GE HealthCare to buy Sofie Biosciences for $945 million to strengthen radiopharma business
GE HealthCare (GEHC) will acquire privately held Sofie Biosciences for $945M in cash, gaining US rights to FAPI-74, a PET imaging agent in late-stage testing. The deal strengthens GEHC's radiopharma business, adding products for its imaging systems and increasing exposure to the growing radiopharmaceuticals market. The transaction is expected to close in the first half of 2027.
How this was made
The 30-second read
Why it matters
The acquisition positions GEHC to capture a larger share of the growing PET imaging drug market, potentially boosting revenue streams.
Market read
The deal is a material M&A event for a major U.S. healthcare company, likely influencing its stock and the radiopharma sector.
What to watch
Regulatory approval for the experimental PET agent and potential competition from other radiopharma players.
Background
GE HealthCare is expanding its diagnostic imaging business through strategic acquisitions, following its $2.3B purchase of Intelerad earlier this year.
Ticker impact
GE HealthCare announced a $945 million cash acquisition of Sofie Biosciences, expanding its radiopharma portfolio.
likely upward pressure as the market prices in the strategic expansion.
Large‑scale M&A in a growth segment typically lifts the acquirer’s stock on the news.
Market effects
Strengthens GEHC's position in the radiopharmaceuticals market, potentially prompting competitors to consider similar moves.
U.S. healthcare and imaging sectors may see increased investor interest.
Adds to broader consolidation trends in medical imaging and diagnostics worldwide.
Counterpoint
If integration challenges arise, the acquisition could strain GEHC's balance sheet and dilute focus.
Key entities
- CompanyGE HealthCare
U.S.-listed medical device and diagnostics firm.
- CompanySofie Biosciences
Privately held radiopharma developer owned by Trilantic.
